Enorama Pharma AB has convened an extraordinary general meeting for 4 December 2026 to determine whether to continue operations or enter liquidation. The board proposes continuing operations, noting that the company's equity is fully restored following a new USD 2,500,000 loan agreement and a debt-to-equity conversion plan with DS Global.
The board proposes that the EGM on 4 December 2026 continue operations instead of liquidation, and the control balance sheet shows equity fully restored - positive for survival. However, the 13 November 2026 supplemental agreement converts outstanding loans (including the new USD 2,500,000 facility) into shares at 0.4 SEK per share, and DS Global could exceed 30% ownership, meaning substantial dilution at a fixed low price. The positive continuation signal and the dilution largely offset each other.
- • Extra general meeting on 4 December 2026 decides on continuing operations versus liquidation
- • Decision on introducing 9% annual interest in the USD 2,500,000 loan agreement with DS Global
- • Major dilution from offset issuance at 0.4 SEK per share
- • DS Global (holding ~29.81%) could exceed 30% ownership via the conversion